ERBB2 L755W

CI-VAR-00002418Explore in graph →NP_004439.2:p.Leu755TrpNM_004448.3:c.2264T>GClinVar 376343 CIViC 40 rs121913470

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB2 L755W	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	2	submitted	EID12234 In the phase 2 DESTINY-Lung02 trial, 152 metastatic NSCLC patients harbouring mutations in ERBB2 (HER2) were treated with the HER2 antibody-drug-conjugate (ADC) trastuzumab deruxtecan (5.4 mg/kg or 6.… (full text at CIViC) PMID 37694347 · Goto et al., 2023 · Open in CIViC	civic
Malignant Breast Neoplasm1
ERBB2 L755W	Neratinib	Predictive	D	Supports Sensitivity Response	5	accepted	EID284 MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay. PMID 23220880 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.